CORDLIFE GROUP

I am puzzled by FIL announcements relating to a no. of stocks -- Sino Grandness, Dukang, Sinwa, CSE, and Cordlife.

The shareholdings for all these stocks did go up -- funnily, all on the same day Dec 2. So I doubt they are actually open market purchases. The box for open mrkt purchases was not ticked in all these announcements.

And the announcements said something abt FMR not being a subst. shareholder of FIL anymore, blah blah. And there was no price nor vol. of shares given, as one would expect.

The people filing the announcements should have been more clear and explicit in explaining the stuff.

PRESS RELEASE
CORDLIFE RAISES ITS INTEREST IN MALAYSIA
LISTED CORD BLOOD BANKING SERVICE
PROVIDER STEMLIFE BERHAD TO 31.81%

- Acquisition of additional 11.89% interest for aggregate consideration
of RM17.66 million
- Transaction to expand the Group’s Asian presence
- Leveraging on economies of scale and scope as a multi-product
healthcare company catering to the mother and child segment

Singapore, 9 December 2013 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), an aspiring multi-product healthcare company catering to the mother and child segment, announced that it has acquired a further 11.89% interest (“Additional Acquisition”) in StemLife Berhad (“StemLife”), an associated company of Cordlife which is listed on the ACE Market of Bursa Malaysia, for a cash payment of approximately RM17.66 million (“Consideration”). Following the Additional Acquisition, Cordlife will hold approximately 31.81% of the issued and paid-up share capital in StemLife. The Consideration for the Additional Acquisition was satisfied by the Group fully
in cash funded through a combination of borrowings and IPO proceeds.

Prior to this, the Group announced on 4 October 2013 that it had completed the
acquisition of an initial 19.92% interest in StemLife (“Initial Acquisition”).

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said, “Malaysia will be one of our key markets going forward. With our acquisition of the additional stake in StemLife, we are well-positioned to further benefit from the tremendous growth opportunities in Malaysia driven by rising affluence and greater health awareness. Cordlife and StemLife have identified many potential synergies between our businesses such as economies of scale and scope in all of StemLife's service/product offerings in Malaysia and potential collaborations with StemLife to offer StemLife's services and products to the Group’s existing markets. As amongst the market leaders in Singapore, Indonesia, Philippines, Hong Kong and India, we believe that the increased stake in StemLife presents Cordlife with the opportunity to further cement its leading position in Asia, and particularly the ASEAN region.”

Valuation and Financial Impact
The Consideration of RM17.66 million for the Additional Acquisition was arrived at after negotiation on an arm's length basis and on a willing-buyer willing-seller basis taking into account, amongst other factors, the aggregate net tangible asset value of StemLife of approximately RM33.17 million as at 30 September 2013. The Consideration is based on an agreed price of RM0.60 per StemLife share, being the same agreed price per StemLife share for the Initial Acquisition.

Based on the unaudited condensed consolidated financial statements of the StemLife group for the third quarter and nine months ended 30 September 2013 as announced by StemLife on 28 November 2013, StemLife has a cash balance of RM73.74 million and a deferred income from operations of RM58.69 million. StemLife generated cash from operating activities of RM6.52 million for the third quarter ended 30 September 2013.

For more information on the Additional Acquisition, Cordlife's shareholders may refer to the announcement made by Cordlife on 9 December 2013 and released on the SGXNET.

Mr Yee continued: “Cordlife is currently benefitting from economies of scale and scope as a multi-product healthcare company, with new products in the pipeline catering to the mother and child segment, on top of its existing core businesses in cord blood banking and umbilical cord tissue banking. The Additional Acquisition will enlarge the Group’s geographical footprint in Asia and allow us to tap into the growth story of emerging Asian nations as part of our economies of scale strategy. With respect to economies of scope, the Group could potentially work with StemLife to cross-sell services and products in Malaysia and Thailand with the increased stake in StemLife. ”

infopub.sgx.com/Apps?A=COW_CorporateAnno...release_09122013.pdf

CORDLIFE Focused Growth-Path Through Economies Of Sale And Scope


* To derive economies of scale, Cordlife is riding on the growth story of emerging Asian nations by expanding its geographical footprint for cord blood and tissue banking business as well as other newly-introduced products catering to the mother and child segment. Initiatives under this strategy include:

* On December 10 2013,Cordlife ups stake in StemLife to 31.81%

* On November 11, 2013, Cordlife announced that it has signed a non-binding term sheet with CCBC, to jointly explore and develop new services based on cellular technologies. This collaboration will enable the Group to capitalise on economies of scale by expanding its geographical reach via CCBC’s local networks.

* On October 4, 2013, the Group announced that it has completed the acquisition of a 19.92% interest in StemLife Berhad (“StemLife”), a company listed on Bursa Malaysia. Through the strategic stake in StemLife, the Group could potentially work with StemLife to cross-sell services and products in Malaysia and Thailand.

* On October 17, 2013, Cordlife announced that it signed a non-binding Memorandum of Understanding with Golden Meditech Holdings Limited in respect of a proposed joint venture (“JV”) in the Shanghai Free Trade Pilot Zone in October 2013. With the proposed JV, Cordlife will be able to market and distribute its products and services in China through Golden Meditech’s local networks.

* In October 2013, the Group’s Indian subsidiary Cordlife India introduced an advanced noninvasive metabolic screening service known as MetaScreen. MetaScreen is a comprehensive set of metabolic screening test specially designed for both newborn babies and adults. The service can detect as many as 110 inborn errors of metabolism from urine samples.

* On June 28, 2013, the Group announced that it has completed the acquisition of Australialisted Life Corporation Limited’s (“LCL”) (previously known as Cordlife Limited) cord blood and cord tissue banking businesses and assets in India, the Philippines, Hong Kong and Indonesia (the “CSCT Acquisition”) for an aggregate consideration of A$5.5 million.

* On November 12, 2012, the Group completed the acquisition of 10% of issued shares in NYSE-listed China Cord Blood Corporation (“CCBC”) and the disposal of our 10% indirect stake in China Stem Cells (South) Company Limited (“CSCS”). To benefit from economies of scope, the Group is also transitioning into a multi-product healthcare company catering to the mother and child segment. In addition to providing cord blood and tissue banking services, the Group is looking to provide other complementary products and services that cater to the mother and child segment. Initiatives under this strategy
include:

* In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child’s umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. This new service was also launched in May 2013 in Singapore and August 2013 in the Philippines.

To fund the Group’s growth initiatives while concurrently strengthening its shareholder base, Cordlife completed a private placement on October 16, 2013 and raised gross proceeds of $33.5 million. For the private placement, the Group issued 26.8 million shares at $1.25 each. Of the total proceeds, $23.5 million will fund its expansion plans abroad, including investments, joint ventures, acquisitions or strategic alliances, while the rest will be used for
general working capital purposes.

The Group is cautiously optimistic that its strong market position and brand equity, coupled with favourable industry factors, will benefit the Group in the next 12 months.

CORDLIFE ANNOUNCEMENT IN RELATION TO THE PAYMENT FOR THE REMAINING 25% OF THE CONSIDERATION TO LIFE CORPORATION LIMITED (FORMERLY KNOWN AS CORDLIFE LIMITED) IN CONNECTION WITH THE SALE AND PURCHASE AGREEMENT DATED 17 MAY 2013 AS AMENDED BY THE SUPPLEMENTAL DEED DATED 27 SEPTEMBER 2013



infopub.sgx.com/Apps?A=COW_CorporateAnno...tof3rdTrancheAnn.pdf

CORDLIFE
Dr. Ho Choon Hou Chairman and Non-Executive of Cordlife on 30/12/2013 bought 60,000 Cordlife shares, average per share SGD 1.198, total cost SGD 71,899.98. This raised his holding from 624,061 shares (0.233%) to 684,061 shares (0.256%).

FIL Limited on 7th January 2014 bought 210,000 Cordlife shares for $247,405 average price per share @ $1.18. This raised its holding from 23,973,000 shares (8.97%) to 24,183,000 shares (9.05%).